Stoneridge Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Stoneridge Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$657K	Buy	+861	New	+$586K	0.43%	74
2025 Q4	–	Sell	-2,360	Closed	-$1.33M	–	156
2025 Q3	$1.33M	Buy	+2,360	New	+$1.33M	0.91%	39
2021 Q3	–	Sell	-950	Closed	-$531K	–	132
2021 Q2	$531K	Buy	+950	New	+$481K	0.26%	82

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Stoneridge Investment Partners's REGN Position: Q2 2026 in Review

Stoneridge Investment Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 861 shares worth $657K. The stake represents 0.43% of the portfolio and ranks #74 among its holdings. This is a return to the name: Stoneridge Investment Partners previously reported a position in REGN as recently as Q3 2025.

Stoneridge Investment Partners first reported a position in REGN in Q2 2021 and has held it in 3 quarters since. The position peaked at $1.33M in Q3 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Stoneridge Investment Partners held 861 shares of Regeneron Pharmaceuticals worth $657K as of Q2 2026.
Regeneron Pharmaceuticals was a new Stoneridge Investment Partners position in Q2 2026.
Regeneron Pharmaceuticals made up 0.43% of Stoneridge Investment Partners's portfolio in Q2 2026, its #74 holding.
Stoneridge Investment Partners first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 3 quarters since.
Stoneridge Investment Partners's Regeneron Pharmaceuticals position peaked at $1.33M in Q3 2025.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.